- Research article
- Open Open Peer Review
Bone marrow transplantation in AML, and socioeconomic class: a UK population-based cohort study
BMC Cancervolume 10, Article number: 514 (2010)
We have previously shown that in the UK mortality in people with Acute Myeloid Leukaemia (AML) was nearly 50% greater among the most socio-economically deprived. The aim of this study was to determine whether AML patients from lower socioeconomic classes had a lower chance of receiving a bone marrow transplant.
Using Hospital Episode Statistics (HES) data, we identified all incident cases of AML admitted to UK hospitals between 1998 and 2007. We calculated the number of bone marrow transplantations undertaken in AML patients, stratifying our results by gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity. We used logistic regression to calculate odds ratios for bone marrow transplantation, adjusting for gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity score.
We identified a total of 23 910 incident cases of AML over this 10-year time period, of whom 1 140 (4.8%) underwent BMT. Bone marrow transplantation declined with increasing socioeconomic deprivation (p for trend < 0.001) such that people in the most deprived socioeconomic quintile were 40% less likely to have a transplant than those in the most advantaged group (Odds Ratio 0.60, 95% confidence interval 0.49, 0.73), even after adjusting for gender, age at diagnosis, year of diagnosis and co-morbidity.
This large cohort study demonstrates that AML patients from lower socioeconomic classes are less likely to undergo bone marrow transplantation than their better off counter-parts.
We have previously shown that while the incidence of Acute Myeloid Leukaemia (AML) in the UK is similar across the spectrum of social class, mortality was nearly 50% greater among the most socioeconomically deprived patients than among the most advantaged. We postulated that this difference in survival might be due to different patterns of treatment, such as bone marrow transplantation (BMT), and/or the presence of greater co-morbidity, such as heart disease and COPD, among patients from lower socioeconomic classes. Previous studies have shown that people from more deprived background are less likely to receive chemotherapy and radiotherapy for a range of cancers including breast, lung and colorectal[3, 4] cancers.
In this study we have used Hospital Episode Statistics (HES) data to determine whether people with AML from lower socioeconomic classes are less likely to receive bone marrow transplantation than those from higher socioeconomic classes. We also wished to determine whether any difference in the use of BMT found was due to greater co-morbidity among more deprived patients than among the better off.
We used anonymised hospital episode statistics (HES) data for this study. These are record-level data administered by The NHS Information Centre for Health and Social Care, on behalf of the Secretary of State for Health. Data are extracted from routine data flows between healthcare providers and commissioners and used to populate the HES datasets. The admitted patient dataset, which includes inpatient and day-case records, was used in this research. Cumulative data are extracted quarterly for this dataset and it is also updated annually. The information contained within HES includes patient demographics such as date of birth, gender and region of residence, details of diagnoses and treatments received, as well as administrative details such as admission and discharge dates, as well as the place patients were treated (NHS Trust or independent sector hospital, for example).
We identified all incident cases of AML admitted to UK hospitals between 1998 and 2007, including those admitted as day-cases. We also identified all admissions for co-existing medical diagnoses recorded in HES for these patients, along with all procedures, including bone marrow transplantation, which they underwent during all of their admissions over this period. Bone marrow transplantation for the purposes of this study means allogeneic stem cell transplantation with cells harvested from peripheral blood or bone marrow.
We calculated the number of bone marrow transplantations undertaken in AML patients, stratifying our results by gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity. We used Townsend Score as the measure of socioeconomic deprivation, which is derived from 2001 census output data and divided into quintiles, with 1 being the least deprived group and 5 being the most deprived. The score is based on a combination of four variables namely: unemployment; car ownership; home ownership and overcrowding, which produce a ranking of a particular small homogenous socio-geographic area of about 150 homes.
We used co-morbid illness data recorded on admission to assign a co-morbidity score to each patient using the Charlson Co-morbidity Index. This scoring takes into account the presence of 19 different medical disease groups, each of which carries a weight ranging from 1 to 6, depending on the relative risk of death within 12 months associated with the presence of the particular disease group. The Charlson Co-morbidity Index has been found to have good reliability and to correlate well with mortality.
We used logistic regression to calculate odds ratios for bone marrow transplantation, adjusting for gender, age at diagnosis, year of diagnosis, degree of socioeconomic deprivation and co-morbidity score. All data management and statistical analyses were conducted using STATAv.10.0.
We identified a total of 23 910 incident cases of AML over this 10-year time period, of whom 1 140 (4.8%) underwent BMT. The numbers of bone marrow transplants performed across various strata in AML are shown in Table 1. A similar proportion of men and women had BMT, about 5%. The frequency of bone marrow transplantation decreased with increasing age at diagnosis, with only 3 transplants recorded in those aged 71 or older. A smaller percentage of patients from lower socioeconomic classes had transplants than those from higher socioeconomic classes. The relationship between socioeconomic class and co-morbidity is shown in Table 2. Between 68 and 70% of AML patients have a Charlson Co-morbidity Score of 0, 14 -16% have a Score of 1, and 16% have a Score of 2 or more, with no significant differences across socio-economic classes in any of the co-morbidity categories.
Odds Ratios for bone marrow transplantation in AML are shown in Table 3. Bone marrow transplantation declines with increasing age at diagnosis after the age of 30 (p for trend < 0.001), as well as with increasing socioeconomic deprivation (p for trend < 0.001). Patients with AML in the most deprived socioeconomic quintile are 40% less likely to have a bone marrow transplantation than those in the most advantaged socioeconomic class (OR 0.60, p < 0.001, 95% C.I. 0.49, 0.73), even after adjusting for gender, age at diagnosis, year of diagnosis and co-morbidity. No statistically significant interaction was found between Townsend score and age, or year of diagnosis. There was, however, statistically significant interaction (p = 0.01) between Townsend score and gender, with greater differences in odds ratios across the socioeconomic class gradient among women than men. Results of logistic regression (Odds Ratios) stratified by gender are shown in Table 4.
This study has shown that people with AML from more deprived socioeconomic classes are less likely to undergo bone marrow transplantation than their counter-parts from more advantaged social classes, even after adjusting for the presence of recorded co-existing disease.
The main strength of this study is the large size of the study population. We were able to study over 23 000 incident cases of AML in the UK using data derived from hospital records. Data also included the co-existing medical conditions of AML patients, which allowed us to adjust for co-morbidity. One drawback, however, was that our data on co-morbidity was based on hospital admission records for those conditions. This means that whilst we should have captured the most severe co-morbid illness we will have missed more minor disease. As a result it is possible that there is some residual confounding by co-morbid illness in this study and that some of the gradient in socioeconomic status and access to bone marrow transplantation is still due to co-morbid disease.
By using routinely collected and available data rather than questionnaires or interviews, we have eliminated any bias in the reporting of socioeconomic class and any social class bias in participation in the study. Bone marrow transplantation recording is also likely to be accurate in hospital records given the highly specialised nature of the procedure. It seems likely to us therefore that the validity of this information is good.
One potential weakness of this study is that we were unable to adjust for the cytogenetic risk group of our AML patients. Based on cytogenetics at presentation, AML patients are classified into good, intermediate, and adverse risk groups, each with very different long term outcomes. Good risk patients in their first remission are not transplanted, whereas adverse risk patients are almost always transplanted (subject to fitness and donor availability). Any bias introduced by this in our results, however, is likely to apply across all social classes, unless patients from lower social classes are more likely to be in the good risk group than those from higher socioeconomic classes, for which there is no evidence. Although there is evidence that patients from lower social classes present later with disease symptoms in general, it is less likely that late presentation is an important factor in AML survival given the acute presentation of the disease and its relatively poor prognosis. For intermediate risk patients, however, it is possible that later presentation may have an impact on the treatment administered and its outcome.
The accuracy of social class classification is imperfect given that Townsend Score is not an individual measure of deprivation. This will have introduced a non-differential bias into our results, if any, i.e. both patients who had had a bone marrow transplant and those who had not will have been similarly affected. Such a bias will have moved odds ratios closer to '1'. It seems then that if we had been able to perfectly adjust for socio-economic deprivation, our results may have shown an even greater class bias.
The validity of co-morbidity recorded in HES data may also be imperfect. Any inaccuracies would, however, apply equally across social class strata and so is unlikely to have introduced bias into these results. Furthermore these results showed no difference in recorded comorbidity across the social classes. Residual confounding cannot be ruled out completely, however, since only comorbidity recorded in the hospital episode data have been taken into account. Other comorbidities not related to hospital admission or not recorded during the admission may have existed which would have resulted in incomplete adjustment for comorbidity.
To our knowledge no studies examining the association between bone marrow transplantation and socioeconomic class have previously been published. Studies have, however, examined the associations between social class and chemotherapy in a number of cancers. Several studies found that lower socioeconomic class predicted under-use of chemotherapy in colorectal cancer (CRC)[3, 4], breast cancer and lung cancer. Two North American studies found that low socioeconomic status was associated with under-use of adjuvant chemotherapy in both breast and colorectal cancers, and postulated that this was in part due to a combination of poor access to care, financial barriers and physicians' assumptions and biases regarding patients from lower socioeconomic classes, such as the availability of social and monetary support, their expectations of treatment and their likely compliance with treatment, for example. A further study concluded that lower incomes, absent or limited insurance cover and poorer education reduced access to high-quality adjuvant chemotherapy, which in turn reduced survival in breast cancer.
In the UK, a Scottish study showed that patients from the poorest deprivation quintile were less likely to receive chemotherapy for lung cancer and colorectal cancer than the most advantaged patients after adjusting for age, tumour stage at diagnosis, health authority and distance from oncology centre. Delay between referral and treatment was similar across all social classes and so did not explain the findings. Although this study did not adjust for comorbidity, another Scottish study which had done so also found poorer survival in colorectal cancer patients from the most deprived socioeconomic quintiles, in a study population which showed no correlation between socioeconomic deprivation and co-morbidity. The findings of these studies, in the UK healthcare setting where access to treatment is equal and free, suggest that decision-making (by both physicians and patients) regarding chemotherapy may be influenced by non-clinical factors.
This large cohort study demonstrates that people with AML from lower socioeconomic classes in the UK are less likely to undergo bone marrow transplantation than their better off counter-parts. Further work is now required to fully understand the reasons for this finding and to ensure equal access to treatment for people from all backgrounds.
Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R: The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009, 9 (1): 252-10.1186/1471-2407-9-252.
Griggs JJ, Culakova E, Sorbero MES, van Ryn M, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH: Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.[see comment]. Journal of Clinical Oncology. 2007, 25 (3): 277-284. 10.1200/JCO.2006.08.3063.
Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J: Impact of deprivation and rural residence on treatment of colorectal and lung cancer. British Journal of Cancer. 2002, 87 (6): 585-590. 10.1038/sj.bjc.6600515.
McGory ML, Zingmond DS, Sekeris E, Bastani R, Ko CY: A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Diseases of the Colon & Rectum. 2006, 49 (3): 319-329.
HESonline. --- Either ISSN or Journal title must be supplied.. [http://www.hesonline.nhs.uk]
The National Digital Archive of Datasets. --- Either ISSN or Journal title must be supplied.. [http://www.ndad.nationalarchives.gov.uk/CRDA/24/DS/1999/1/4/detail.html]
Hall W, Ramachandran R, Narayan S, Jani A, Vijayakumar S: An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004, 4 (1): 94-10.1186/1471-2407-4-94.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, et al: The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood. 1998, 92 (7): 2322-2333.
Muss HB: Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. Journal of the National Cancer Institute Monographs. 2001, 52-55. 30
Munro AJ, Bentley AHM: Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care (Engl). 2004, 13 (3): 254-262. 10.1111/j.1365-2354.2004.00480.x.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/514/prepub
The authors declare that they have no competing interests.
FB conducted the data management, performed the statistical analyses and drafted the manuscript. EDG contributed to revising the manuscript for intellectual content. RH conceived of the study, acquired the data and edited the manuscript. All authors read and approved the final manuscript.